[HTBX] Heat Biologics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.88 Change: -0.04 (-4.13%)
Ext. hours: Change: 0 (0%)

chart HTBX

Refresh chart

Strongest Trends Summary For HTBX

HTBX is in the medium-term down -35% below S&P in 2 months and down -45% below S&P in 4 months and down -63% in 1 year. In the long-term down -96% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Heat Biologics, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer-associated antigens together with a potent immune adjuvant. The company?s products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase I/II clinical trials for the bladder cancer treatment. It is also developing a cell line for the treatment of ovarian and triple negative breast cancer; and HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-58.55% ROE-68.91% ROI
Current Ratio9.85 Quick Ratio Long Term Debt/Equity Debt Ratio0.12
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11.13 M Cash From Investing Activities-110 K Cash From Operating Activities-4.46 M Gross Profit
Net Profit-3.91 M Operating Profit-3.98 M Total Assets22.83 M Total Current Assets22.15 M
Total Current Liabilities2.25 M Total Debt2.73 M Total Liabilities3.43 M Total Revenue
Technical Data
High 52 week2.87 Low 52 week0.84 Last close0.84 Last change-2.75%
RSI14.09 Average true range0.07 Beta1.25 Volume871.26 K
Simple moving average 20 days-17.09% Simple moving average 50 days-25.87% Simple moving average 200 days-42.97%
Performance Data
Performance Week-14.7% Performance Month-25.96% Performance Quart-41.79% Performance Half-47.9%
Performance Year-53.62% Performance Year-to-date-13.87% Volatility daily2.84% Volatility weekly6.36%
Volatility monthly13.04% Volatility yearly45.16% Relative Volume229.83% Average Volume511.19 K
New High New Low

News

2019-06-12 13:30:00 | HTBX: INDs To Be Filed Soon

2019-06-03 06:55:00 | Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

2019-05-23 11:09:20 | Is Heat Biologics, Inc.'s NASDAQ:HTBX CEO Overpaid Relative To Its Peers?

2019-05-20 08:30:00 | Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

2019-05-15 07:30:00 | Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

2019-05-06 07:00:00 | Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

2019-04-18 17:30:00 | Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

2019-04-11 09:30:00 | HTBX: 2018 Financial & Operational Results

2019-04-02 08:00:00 | Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019

2019-03-28 07:30:00 | Heat Biologics Reports 2018 Results and Provides Corporate Update

2019-03-21 07:00:00 | Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy

2019-03-11 10:40:00 | HTBX: HS-110 Interim Update

2019-03-05 09:25:00 | Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

2019-02-28 17:00:00 | Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

2019-02-26 09:45:00 | These Four Healthcare Stocks Are Heating Up On Tuesday

2019-02-13 10:03:27 | What Type Of Shareholder Owns Heat Biologics, Inc.’s NASDAQ:HTBX?

2019-01-14 14:15:00 | UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDAR in Non-Small Cell Lung Cancer Trial

2019-01-14 08:00:00 | Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDAR in Non-Small Cell Lung Cancer Trial

2019-01-10 08:27:52 | The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

2019-01-10 06:30:00 | Heat Biologics Provides Clinical and Business Update

2019-01-08 06:30:00 | Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

2019-01-04 07:00:00 | Heat Biologics to Present at Biotech Showcase 2019 in California

2018-12-03 10:15:00 | HTBX: Plenty of Catalysts in 2019

2018-11-27 08:38:42 | Durham company rakes in another $13.8M through public offering

2018-11-26 16:00:00 | Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering

2018-11-26 06:00:00 | Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum

2018-11-23 08:15:00 | Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics — What Drives Growth in Today's Competitive Landscape

2018-11-21 15:21:00 | Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

2018-11-21 13:37:33 | Should You Be Concerned About Heat Biologics Inc’s NASDAQ:HTBX Historical Volatility?

2018-11-21 08:04:35 | The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

2018-11-21 07:30:00 | Heat Biologics, Inc. Prices $12,000,000 Public Offering

2018-11-20 15:10:00 | Heat Biologics, Inc. Announces Proposed Public Offering

2018-11-15 07:00:00 | Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update

2018-10-22 07:00:00 | Heat Biologics to Present at Precision: Lung Cancer World R&D Summit

2018-10-19 07:00:00 | Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City

2018-10-10 07:00:00 | Heat Biologics to Present at the 2018 BIO Investor Forum

2018-10-04 07:00:00 | Heat Biologics’ Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator

2018-09-26 15:16:17 | What does Heat Biologics Inc’s NASDAQ:HTBX Balance Sheet Tell Us About Its Future?

2018-08-29 09:45:00 | HTBX: Multiple Milestones on the Horizon

2018-08-29 07:00:00 | Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

2018-08-15 16:21:04 | Heat Biologics Stock Is a Worthwhile, Speculative Bet

2018-08-14 07:30:00 | Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update

2018-07-30 07:00:00 | Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks

2018-07-16 09:45:00 | HTBX: Heat Biologics: Making an ImPACT on Cancer

2018-06-29 07:10:00 | Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

2018-06-06 13:22:21 | Is Heat Biologics Inc NASDAQ:HTBX Excessively Paying Its CEO?

2018-05-30 07:00:00 | Heat Biologics to Present at the 2018 BIO International Convention

2018-05-25 07:15:00 | Wired News - Clementia Announced Encouraging Phase-2 Part B Data Evaluating Palovarotene for FOP Treatment

2018-05-24 07:15:00 | Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

2018-05-16 08:10:00 | Today’s Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals